Caitlin E. Hill

Caitlin E. Hill

Auto-generated profile, based on publicly available information

Caitlin E. Hill

Burke Neurological Institute White Plains New York USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2021 in Glia
Verified
Journal Article
Closed access
PDF file
BDBrian David
Brian David
JCJessica J. Curtin
Jessica J. Curtin
JBJennifer L. Brown
Jennifer L. Brown
DCDavid J. C. Coutts
David J. C. Coutts
NBNathan C. Boles
Nathan C. Boles
CHCaitlin E. Hill
Caitlin E. Hill


14 July 2023 in Experimental Neurology
Verified
Journal Article
Closed access
MMMariajose Metcalfe
Mariajose Metcalfe
BDBrian David
Brian David
BLBrett C. Langley
Brett C. Langley
CHCaitlin E. Hill
Caitlin E. Hill

5 September 2019 in eneuro
Verified
Journal Article
Open access
PDF file
BDBrian David
Brian David
JCJessica J. Curtin
Jessica J. Curtin
DGDavid C. Goldberg
David C. Goldberg
KSKerri Scorpio
Kerri Scorpio
VKVeena Kandaswamy
Veena Kandaswamy
CHCaitlin E. Hill
Caitlin E. Hill
Cellular transplantation is in clinical testing for a number of central nervous system disorders, including spinal cord injury (SCI). One challenge is acute transplanted cell death. To prevent this death, there is a need to both establish when the death occurs and develop approaches to mitigate its effects. Here, using luciferase (luc) and green fluorescent protein (GFP) expressing Schwann cell (SC) transplants in the contused thoracic rat spinal cord 7 d postinjury, we establish viain vivobioluminescent (IVIS) imaging and stereology that cell death occurs prior to 2–3 d postimplantation. We then test an alternative approach to the current paradigm of enhancing transplant survival by including multiple factors along with the cells. To stimulate multiple cellular adaptive pathways concurrently, we activate the hypoxia-inducible factor 1α (HIF-1α) transcriptional pathway. Retroviral expression of VP16-HIF-1α in SCs increased HIF-α by 5.9-fold and its target genes implicated in oxygen transport and delivery (VEGF, 2.2-fold) and cellular metabolism (enolase, 1.7-fold). In cell death assaysin vitro, HIF-1α protected cells from H2O2-induced oxidative damage. It also provided some protection against camptothecin-induced DNA damage, but not thapsigargin-induced endoplasmic reticulum stress or tunicamycin-induced unfolded protein response. Following transplantation, VP16-HIF-1α increased SC survival by 34.3%. The increase in cell survival was detectable by stereology, but not byin vivoluciferase orex vivoGFP IVIS imaging. The results support the hypothesis that activating adaptive cellular pathways enhances transplant survival and identifies an alternative pro-survival approach that, with optimization, could be amenable to clinical translation.

19 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MMMariajose Metcalfe
Mariajose Metcalfe
BDBrian David
Brian David
BLBrett C. Langley
Brett C. Langley
CHCaitlin E. Hill
Caitlin E. Hill
Spinal cord injury (SCI)-induced tissue damage spreads to neighboring spared cells in the hours, days and weeks following injury leading to exacerbation of tissue damage and functional deficits. Among the biochemical changes is the rapid reduction of cellular nicotinamide adenine dinucleotide (NAD + ), an essential coenzyme for energy metabolism and an essential cofactor for non-redox NAD + -dependent enzymes with critical functions in sensing and repairing damaged tissue. NAD + depletion propagates tissue damage. Augmenting NAD + by exogenous application of NAD + , its synthesizing enzymes or its cellular precursors mitigates tissue damage. Among the NAD + precursors, nicotinamide riboside (NR) appears to be particularly well-suited for clinical translation. It safely and effectively augments cellular NAD + synthesis in a variety of species, including rats and humans, and in a variety of preclinical models, elicits tissue protection. Evidence of NR’s efficacy in the context of SCI repair, however, is currently lacking. These studies tested the hypothesis that administration of NR can effectively enhance NAD + in the injured spinal cord and that augmenting spinal cord NAD + protects spinal cord tissue from injury and leads to improvements in locomotor recovery. The results show that intraperitoneal administration of NR (500 mg/kg), administered four days prior to and two weeks following a mid-thoracic contusion-SCI injury, doubles spinal cord NAD + levels in Long-Evans rats. NR administration preserves spinal cord tissue after injury including neurons and axons, as determined by gray and white matter sparing, and enhances motor function, as assessed by the BBB subscore and missteps on the horizontal ladderwalk. Collectively, the findings demonstrate that administration of the NAD + precursor, NR, to elevate NAD + within the injured spinal cord mitigates the tissue damage and functional decline that occurs following SCI. HIGHLIGHTS: Nicotinamide Riboside augments spinal cord nicotinamide adenine dinucleotide (NAD + ). Elevating NAD + protects spinal cord tissue from spinal cord injury (SCI). Elevating NAD + enhances motor recovery following SCI.